Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Charly50on Apr 12, 2021 4:12am
186 Views
Post# 32975749

RE:RE:RE:Buy Out

RE:RE:RE:Buy Out
Leading pharmaceutical expert for therapeutics in regenerative medicine strengthens the Sernova team in corporate development and strategic planning
 
LONDON, ONTARIO, July 16, 2020 - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FWB: PSH), a regenerative medicine company specializing in clinical trials, announced today that an international advisory board has been established and Dr. Anke M. Schulte will be a member of this advisory board. Dr. Schulte is an internationally renowned expert in diabetes, cell therapy and regenerative medicine and has been with SANOFI, a leading international pharmaceutical company, for 19 years.
 
The members of Sernova's international advisory board (Global Advisory Board) provide their expertise and strategic know-how to support the ongoing development and future commercialization of Sernova's novel platform for therapeutics in regenerative medicine and cell therapy. They are also available to advise the company on clinical development programs, expansion plans, acquisitions of additional technologies, and collaborations and partnerships in the pharmaceutical sector.

But 2.87 shouldn't be an issue.
<< Previous
Bullboard Posts
Next >>